CO2022007273A2 - Análogos de insulina novedosos y usos de estos - Google Patents

Análogos de insulina novedosos y usos de estos

Info

Publication number
CO2022007273A2
CO2022007273A2 CONC2022/0007273A CO2022007273A CO2022007273A2 CO 2022007273 A2 CO2022007273 A2 CO 2022007273A2 CO 2022007273 A CO2022007273 A CO 2022007273A CO 2022007273 A2 CO2022007273 A2 CO 2022007273A2
Authority
CO
Colombia
Prior art keywords
insulin analogs
analogs
novel insulin
diabetes
medical conditions
Prior art date
Application number
CONC2022/0007273A
Other languages
English (en)
Inventor
Madsen, (Fallecido) Peter
Mathias Norrman
Frantisek Hubalek
Helle Birk Olsen
Thomas Børglum Kjeldsen
Jeppe Sturis
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of CO2022007273A2 publication Critical patent/CO2022007273A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Abstract

La presente invención pertenece al campo terapéutico de los fármacos para las afecciones médicas relacionadas con la diabetes. Más específicamente, la invención se refiere a análogos de insulina de la insulina humana. La invención proporciona composiciones farmacéuticas que comprenden tales análogos de insulina y los usos de tales análogos para el tratamiento o prevención de afecciones médicas relacionadas con la diabetes.
CONC2022/0007273A 2019-12-11 2022-05-27 Análogos de insulina novedosos y usos de estos CO2022007273A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19215315 2019-12-11
PCT/EP2020/085541 WO2021116292A1 (en) 2019-12-11 2020-12-10 Novel insulin analogues and uses thereof

Publications (1)

Publication Number Publication Date
CO2022007273A2 true CO2022007273A2 (es) 2022-08-19

Family

ID=68886882

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0007273A CO2022007273A2 (es) 2019-12-11 2022-05-27 Análogos de insulina novedosos y usos de estos

Country Status (16)

Country Link
US (3) US11498951B2 (es)
EP (1) EP4073097A1 (es)
JP (2) JP6995284B2 (es)
KR (1) KR102427426B1 (es)
CN (1) CN114787184A (es)
AR (1) AR120717A1 (es)
AU (1) AU2020402135A1 (es)
BR (1) BR112022009510A2 (es)
CA (1) CA3159114A1 (es)
CL (1) CL2023000086A1 (es)
CO (1) CO2022007273A2 (es)
IL (1) IL292762A (es)
MX (2) MX2022006251A (es)
PE (1) PE20221260A1 (es)
TW (1) TWI773009B (es)
WO (1) WO2021116292A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018002416A2 (pt) 2015-08-25 2018-09-18 Novo Nordisk As derivados de insulina e seus usos médicos
KR20230057686A (ko) 2021-10-22 2023-05-02 주식회사 엘지에너지솔루션 캡 어셈블리 및 이를 포함하는 이차 전지

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DK105489D0 (da) 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
JP3122128B2 (ja) 1989-12-21 2001-01-09 ノボ ノルディスク アクティーゼルスカブ ペプチド製剤
EP1132404A3 (en) 1993-09-17 2002-03-27 Novo Nordisk A/S Acylated insulin
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
ZA954983B (en) 1994-06-17 1996-02-14 Novo Nordisk As N-terminally extended proteins expressed in yeast
US5922678A (en) 1996-06-28 1999-07-13 Eli Lilly And Company Methods for treating diabetes
DE69735242T2 (de) 1996-12-20 2006-09-21 Novo Nordisk A/S N-terminal verlängerte proteine exprimiert in hefe
AU742591B2 (en) 1997-03-20 2002-01-10 Novo Nordisk A/S Zinc free insulin crystals for use in pulmonary compositions
HUP0004169A3 (en) 1997-10-24 2001-06-28 Lilly Co Eli Insoluble insulin compositions and process for production thereof
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US7193035B2 (en) 2002-10-29 2007-03-20 Sanofi-Aventis Deutschland Gmbh Crystals of insulin analogs and processes for their preparation
JP5697831B2 (ja) 2003-12-03 2015-04-08 ノヴォ ノルディスク アー／エス 単鎖インシュリン
US20100216690A1 (en) 2005-03-18 2010-08-26 Novo Nordisk A/S Pegylated Single-Chain Insulin
ATE482977T1 (de) 2006-02-27 2010-10-15 Novo Nordisk As Insulinderivate
EP1996709A2 (en) 2006-03-13 2008-12-03 Novo Nordisk A/S Acylated single chain insulin
ITRG20070003A1 (it) 2007-07-17 2009-01-18 Salvatore Lucifora Metodo e sistema informatico per analizzare le prestazioni e dimensionare una cella underlay/overlay di un sistema di telecomunicazione cellulare
ES2558930T3 (es) 2007-08-13 2016-02-09 Novo Nordisk A/S Análogos de la insulina de acción rápida
KR20100053561A (ko) 2007-08-15 2010-05-20 노보 노르디스크 에이/에스 아실 및 알킬렌 글리콜 부분을 갖는 인슐린 유사체
WO2009022006A1 (en) 2007-08-15 2009-02-19 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
US9260502B2 (en) 2008-03-14 2016-02-16 Novo Nordisk A/S Protease-stabilized insulin analogues
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
CN102065903B (zh) 2008-04-01 2015-02-18 诺沃-诺迪斯克有限公司 胰岛素清蛋白缀合物
WO2011000823A1 (en) 2009-06-30 2011-01-06 Novo Nordisk A/S Insulin derivatives
ES2552401T3 (es) 2009-11-02 2015-11-27 Novo Nordisk A/S Solución farmacéutica de albúmina unida no covalentemente e insulina acilada
CN102947331B (zh) 2010-06-23 2016-08-03 诺沃—诺迪斯克有限公司 包含额外的二硫键的胰岛素类似物
JP2013541500A (ja) 2010-07-28 2013-11-14 スマートセルズ・インコーポレイテツド 組換えレクチン、結合部位修飾レクチンおよびそれらの用途
EP2627670A2 (en) 2010-10-15 2013-08-21 Novo Nordisk A/S Novel n-terminally modified insulin derivatives
EP2720711A1 (en) 2011-06-15 2014-04-23 Novo Nordisk A/S Multi substituted insulins
AU2012328407A1 (en) 2011-10-27 2014-05-22 Case Western Reserve University Ultra-concentrated rapid-acting insulin analogue formulations
KR20140104994A (ko) 2011-12-15 2014-08-29 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 인간 인슐린 유사체 및 이의 아실화 유도체
BR112015023071A2 (pt) 2013-03-14 2017-07-18 Univ Indiana Res & Tech Corp conjugados de insulina-incretina
BR112016007176A2 (pt) 2013-10-04 2018-01-23 Merck Sharp & Dohme conjugado, composição, usos de um conjugado e de uma composição, e, método para tratar um indivíduo que tem diabete
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
BR112018002416A2 (pt) 2015-08-25 2018-09-18 Novo Nordisk As derivados de insulina e seus usos médicos
US20190010206A1 (en) 2015-08-25 2019-01-10 Novo Nordisk A/S Novel Insulin Derivatives and the Medical Uses Hereof
CN105440125B (zh) 2015-11-25 2019-09-24 华润昂德生物药业有限公司 地特胰岛素或其类似物的制备方法
WO2019125879A2 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery

Also Published As

Publication number Publication date
US20230192801A1 (en) 2023-06-22
KR20210141748A (ko) 2021-11-23
JP2021091685A (ja) 2021-06-17
IL292762A (en) 2022-07-01
PE20221260A1 (es) 2022-08-16
JP6995284B2 (ja) 2022-01-14
CN114787184A (zh) 2022-07-22
WO2021116292A1 (en) 2021-06-17
CA3159114A1 (en) 2021-06-17
US20240141011A1 (en) 2024-05-02
TW202136289A (zh) 2021-10-01
AU2020402135A1 (en) 2022-06-02
US11498951B2 (en) 2022-11-15
BR112022009510A2 (pt) 2022-08-16
MX2022006251A (es) 2022-06-22
US20210179685A1 (en) 2021-06-17
KR102427426B1 (ko) 2022-08-01
AR120717A1 (es) 2022-03-09
MX2023000398A (es) 2023-02-02
EP4073097A1 (en) 2022-10-19
CL2023000086A1 (es) 2023-08-04
TWI773009B (zh) 2022-08-01
JP2021119193A (ja) 2021-08-12

Similar Documents

Publication Publication Date Title
AR099569A1 (es) Derivados de insulina y los usos médicos de estos
CO2022007273A2 (es) Análogos de insulina novedosos y usos de estos
CO2019006017A2 (es) Composiciones farmacéuticas que contienen insulina
AR106364A1 (es) Derivados de insulina y sus usos médicos
ECSP19083930A (es) Compuesto de insulina acilada
BR112015022096A2 (pt) moduladores de canal de sódio para o tratamento da dor
MX368504B (es) Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos.
ECSP12012171A (es) Composiciones farmacéuticas del compuesto espiro-oxindol para administración tópica y sus usos como agentes terapéuticos
ECSP13013068A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2
BR112016005271A2 (pt) Moduladores de canais de sódio para o tratamento da dor e do diabetes
CO2019007409A2 (es) Derivados de la pirimidin enona tricíclica para la inhibición de rorγ y otros usos
DOP2017000123A (es) Análogos de urea unidos sustituidos como moduladores de sirtuina
CL2022003187A1 (es) Compuestos de insulina acilada de acción temporal prolongada
CO2022000749A2 (es) Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos
JOP20210201A1 (ar) مركب لخفض جلوكوز الدم
CO2022016899A2 (es) Moduladores de il-17a
CO2021000229A2 (es) Compuestos de pirazol e imidazol para la inhibición de il-17 y rorgamma
BR112021009616A8 (pt) Composição cicatrizante que compreende água eletrolisada e máscara de aplicação cutânea
CO2020002500A2 (es) Análogos de insulina acilados novedosos y usos de estos
BR112017015597A2 (pt) moduladores dos receptores da adenosina a3
UY36354A (es) Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y tratamiento de la diabetes
EA201891761A1 (ru) Новые биароматические соединения пропинила, фармацевтические и косметические композиции, их содержащие, и их применение
BR102018010523A2 (pt) peptídeo, composição farmacêutica compreendendo o mesmo e uso